ОЦЕНКА НАРУШЕНИЙ В СИСТЕМЕ ГЕМОСТАЗА ПРИ ИММУННОМ МИКРОТРОМБОВАСКУЛИТЕ
Keywords:
Key words: immune microthrombovasculitis, hemostasis system, thrombus formation, activation of blood clotting.Abstract
Material and methods. The study included 52 patients with IMTV, who, according to the stage of the disease. All the subjects were under observation or inpatient treatment at the Khorezm Regional Multidisciplinary Medical Center (HRMMC). The control group consisted of conditionally healthy persons of comparable age without immunocomplex pathologies and disturbances in the hemostasis system (n= 30).
References
Берман Ю.О., Давыдкин И.Л., Кривова С.П., Хайретдинов Р.К. Влияние мутаций системы гемостаза на течение геморрагического васкулита. Гематол. и трансфузиол., 2014, т. 59, № 1. С. 33-34.
Гуляев С.В., Стрижаков Л.А., Моисеев С.В., Фомин В.В. От пурпуры Шенлейна–Геноха до IgА-васкулита: патогенетические аспекты болезни. Терапевтический архив. 2018; 10: 109-114.
Кудряшова М.А. Прогностические факторы течения и исхода болезни Шенлейна-Геноха у детей. Автореф. дис., Москва, 2015, С.24.
Кудряшова М.А., Подчерняева Н.С., Фролкова Е.В. Значение показателей антигена фактора фон Виллебранда и Д-димера для оценки активности болезни Шенлейна-Геноха у детей// Сборник тезисов XXI национального конгресса «Человек и лекарство». – 7-11 апреля 2014г., Москва. С. 66-67.
Aleyd E., van Hout M.W., Ganzevles S.H., Hoeben K.A., Everts V., Bakema J.E. et al. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcalpha receptor I. J Immunol 2014;192:2374–83.
Audemard-Verger A., Pillebout Е., Guillevin L.,Thervet Е., Terrier В. IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects, Autoimmun Rev (2015), Р. 1-7. http://dx.doi.org/10.1016/j.autrev.2015.02.003.
Brogan P., Eleftheriou D. Vasculitis update: pathogenesis and biomarkers. Pediatric Nephrology. February 2018, Volume 33, Issue 2, pp 187–198.
Byun J.W., Song H.J., Kim L. et al. Predictive factors of relapse in adult with Henoch–Schönlein purpura. Am J Dermatopathol 2012; 34:139–144.
Calvo-Río V., Loricera J., Mata C. et al. Henoch–Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore) 2014; 93:106–113.
Calvo-Río V., Loricera J., Ortiz-Sanjuán F. et al. Revisiting clinical differences between hypersensitivity vasculitis and Henoch–Schönlein purpura in adults from a defined population. Clin Exp Rheumatol 2014; 32 suppl 82:S34–S40.
Calvo-Río V., Hernández J. L., Ortiz-Sanjuán F. et al. Relapses in patients with Henoch–Schönlein purpura analysis of 417 patients from a single center. Medicine (Baltimore). 2016 Jul; 95(28): e4217. doi: 10.1097/MD.0000000000004217.
Dalt L. D., Zerbinati C., Strafella M. S., et. al. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics, 2016, 42:60 https://doi.org/10.1186/s13052-016-0267-2.
González-Gay M.A., Blanco R., Pina T. IgA vasculitis (Henoch-Schönlein Purpura). In: Ball GV, Fessler BJ, Bridges SL, editors. Oxford Textbook of Vasculitis. Oxford: Oxford University Press; 2014. p. 527–46.
